Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Zimmer Biomet : Swings to 2Q Loss Amid Elective-Surgery Decline

08/04/2020 | 07:13am EST

By Matt Grossman

 

Zimmer Biomet Holdings Inc. on Tuesday swung to a second-quarter loss as revenue declined amid lower volumes of elective surgeries during the Covid-19 pandemic.

However, the company reported a small per-share adjusted profit, beating analysts' expectations for an adjusted loss.

The Warsaw, Ind.-based company, which makes orthopedic medical products, recorded a second-quarter loss of $206.6 million, or $1 a share, compared with a profit of $133.7 million, or 65 cents a share, in the same three-month period a year earlier.

On an adjusted basis, Zimmer Biomet earned a profit of 5 cents a share. Analysts had expected an adjusted loss of 71 cents a share, according to FactSet.

Revenue in the latest quarter declined to $1.23 billion, from $1.99 billion in the year-earlier period. Analysts had forecast revenue of $921 million.

Zimmer Biomet declined to offer forward-looking guidance. Despite a recovery in elective-surgery volumes, the pandemic's continued impact is uncertain, it said.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

All news about ZIMMER BIOMET HOLDINGS
11/18ZIMMER BIOMET : to Present at 2020 Evercore ISI HealthCONx Conference and Piper ..
AQ
11/17ZIMMER BIOMET : to Present at 2020 Evercore ISI HealthCONx Conference and Piper ..
PR
11/09ZIMMER BIOMET : Announces Third Quarter 2020 Financial Results
AQ
11/06ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
AQ
11/06ZIMMER : 3Q Earnings Snapshot
AQ
11/06ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition (fo..
AQ
11/06ACELRX PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results
AQ
11/06ZIMMER BIOMET : Announces Preliminary Results from mymobility Clinical Study at ..
AQ
11/06ZIMMER BIOMET : Announces Third Quarter 2020 Financial Results
PR
11/05BACTIGUARD : Interim report for Q3 2020
AQ
More news
Financials (USD)
Sales 2020 7 059 M - -
Net income 2020 -167 M - -
Net Debt 2020 6 769 M - -
P/E ratio 2020 -183x
Yield 2020 0,65%
Capitalization 31 025 M 31 025 M -
EV / Sales 2020 5,35x
EV / Sales 2021 4,49x
Nbr of Employees 19 900
Free-Float 66,5%
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 157,07 $
Last Close Price 149,68 $
Spread / Highest target 16,9%
Spread / Average Target 4,94%
Spread / Lowest Target -29,2%
EPS Revisions
Managers
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Kenneth R. Tripp Senior VP-Global Operations & Logistics
Suketu P. Upadhyay Executive VP, Chief Financial & Accounting Officer
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS0.00%31 025
ABBOTT LABORATORIES22.51%188 597
MEDTRONIC PLC-0.12%151 957
BECTON, DICKINSON AND COMPANY-16.36%65 936
HOYA CORPORATION32.49%48 567
BAXTER INTERNATIONAL INC.-9.84%38 511